Thrombotic and hemorrhagic complications in COVID-19.

Abstract

Background. In some cases, a new coronavirus infection demonstrates non-standard clinical manifestations, an integral characteristic of which is a tendency to thrombotic and hemorrhagic complication.Objective. To study the predisposing factors for the development of thrombotic and hemorrhagic complications in patients with COVID-19.Design and methods. The work was based on observations of 403 patients who were hospitalized for pneumonia of viral etiology (COVID-19). The features of comorbid pathology, markers of inflammation and coagulation, characteristics of the identified complications in the main group (75 people who had thrombotic and hemorrhagic complications) were prospectively collected in comparison with the control (328 patients), where no such consequences were detected.Results. There were no significant differences between the groups in terms of age and gender. In the main group, a large number of overweight patients were registered in comparison with the control. The levels of CRP, ferritin, and D-dimer in patients with complications significantly exceeded the reference values more often. Among the complications, spontaneous hematomas, gastrointestinal bleeding, acute cerebral circulatory disorders, acute myocardial infarction and venous thromboembolic complications were recorded.Conclusion. In patients with thrombotic and hemorrhagic complications of COVID-19, the level of markers of the inflammatory process (CRP, ferritin) increases. These negative consequences are most characteristic for patients with chronic kidney disease, severe hypertension, COPD and generalized atherosclerotic process (myocardial infarction, stroke).